The UK’s National Institute for Health and Care Excellence (NICE) has recommended against NHS coverage of Roche’s Polivy (polatuzumab vedotin) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who can’t have a hematopoietic stem cell transplant.
The institute noted questioned the combination therapy’s cost-effectiveness. “It is considered a life-extending treatment at the end of life, but the cost-effectiveness estimates are too uncertain” for NHS funding, NICE said.
NICE did acknowledge that the trial data shows Polivy, when taken with rituximab and bendamustine, can help to delay disease progression. It can also extend the lives of patients, but it’s unclear by how much until final trial data is released.
Polivy received EU clearance in January for patients with previously treated aggressive lymphoma.